BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30197357)

  • 1. Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience.
    Onec B; Okutan H; Albayrak M; Can ES; Aslan V; Koluman BU; Kosemehmetoglu OS; Albayrak A
    J Cancer Res Ther; 2018; 14(5):1105-1111. PubMed ID: 30197357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
    Radujkovic A; Dietrich S; Bochtler T; Krämer A; Schöning T; Ho AD; Dreger P; Luft T
    Eur J Haematol; 2014 Aug; 93(2):112-7. PubMed ID: 24628527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
    Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
    Vives S; Martínez-Cuadrón D; Bergua Burgues J; Algarra L; Tormo M; Martínez-Sánchez MP; Serrano J; Herrera P; Ramos F; Salamero O; Lavilla E; López-Lorenzo JL; Gil C; Vidriales B; Falantes JF; Serrano A; Labrador J; Sayas MJ; Foncillas MÁ; Amador Barciela ML; Olave MT; Colorado M; Gascón A; Fernández MÁ; Simiele A; Pérez-Encinas MM; Rodríguez-Veiga R; García O; Martínez-López J; Barragán E; Paiva B; Sanz MÁ; Montesinos P;
    Cancer; 2021 Jun; 127(12):2003-2014. PubMed ID: 33626197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
    Lao Z; Yiu R; Wong GC; Ho A
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):54-61. PubMed ID: 25545192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.
    Baba Y; Hida N; Sambe T; Abe M; Kabasawa N; Sakai H; Yoshimura K; Fukuda T
    Anticancer Res; 2024 May; 44(5):2003-2007. PubMed ID: 38677735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide.
    Tsurumi H; Kanemura N; Hara T; Kasahara S; Yamada T; Sawada M; Oyama M; Moriwaki H
    J Cancer Res Clin Oncol; 2007 Aug; 133(8):547-53. PubMed ID: 17453240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
    Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
    Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azacitidine and its role in the upfront treatment of acute myeloid leukemia.
    Raslan O; Garcia-Horton A
    Expert Opin Pharmacother; 2022 Jun; 23(8):873-884. PubMed ID: 35695017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.
    Craddock CF; Houlton AE; Quek LS; Ferguson P; Gbandi E; Roberts C; Metzner M; Garcia-Martin N; Kennedy A; Hamblin A; Raghavan M; Nagra S; Dudley L; Wheatley K; McMullin MF; Pillai SP; Kelly RJ; Siddique S; Dennis M; Cavenagh JD; Vyas P
    Clin Cancer Res; 2017 Nov; 23(21):6430-6440. PubMed ID: 28765326
    [No Abstract]   [Full Text] [Related]  

  • 12. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
    Schaich M; Illmer T; Aulitzky W; Bodenstein H; Clemens M; Neubauer A; Repp R; Schäkel U; Soucek S; Wandt H; Ehninger G;
    Haematologica; 2002 Aug; 87(8):808-15. PubMed ID: 12161356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
    Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
    Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.
    Tombak A; Uçar MA; Akdeniz A; Tiftik EN; Gören Şahin D; Akay OM; Yıldırım M; Nevruz O; Kis C; Gürkan E; Solmaz ŞM; Özcan MA; Yıldırım R; Berber İ; Erkurt MA; Fıratlı Tuğlular T; Tarkun P; Yavaşoğlu İ; Doğu MH; Sarı İ; Merter M; Özcan M; Yıldızhan E; Kaynar L; Mehtap Ö; Uysal A; Şahin F; Salim O; Sungur MA
    Turk J Haematol; 2016 Dec; 33(4):273-280. PubMed ID: 27095141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
    Garcia-Manero G; Kazmierczak M; Wierzbowska A; Fong CY; Keng MK; Ballinari G; Scarci F; Adès L
    Leuk Res; 2024 May; 140():107480. PubMed ID: 38499457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
    J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.